Apogee Therapeutics, Inc. (APGE), a clinical-stage biotechnology company, announced Wednesday positive 16-week data from Part B of the Phase 2 APEX clinical trial of zumilokibart (APG777), a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe AD.
The trial met all its primary and secondary endpoints with high statistical significance including 65.9% of patients treated with mid-dose zumilokibart achieving EASI-75 (41.9% placebo adjusted).
Based on these dose optimization results and subject to regulatory interactions, Apogee plans to move forward with the mid-dose, which achieved the best clinical activity of the three doses tested and was well-tolerated, in its Phase 3 trials in the second half of 2026.
The company also announced a $1.3 billion Strategic financing collaboration with Blackstone Life Sciences that is expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE.
In Wednesday's pre-market trading, TGT is trading on the NYSE at $53.76, up $2.52 or 4.93 percent.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.